Ipilimumab-Nivolumab
1 product
5 abstracts
Abstract
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).Org: Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, NHLBI, NIH, Department of Surgery, Loyola University Chicago, Department of Transfusion Medicine, Clinical Center, NIH, Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institute, National Institutes of Health, National Institutes of Health Clinical Center Department of Laboratory Medicine,
Abstract
Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).Org: King's College London, Guy's and St. Thomas' NHS Foundation Trust, Guy's and St. Thomas' Hospital, Guys' and St. Thomas' NHS Foundation Trust,
Abstract
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China, Guangdong Provincial People's Hospital,
Abstract
Outcome analysis of immunotherapy and possible prognostic role of pretreatment neutrophil-lymphocyte ratio in lung cancer: An Appalachian study.Org: Marshall University School of Medicine, Edwards Cancer Center, Marshall University Joan C. Edwards School of Medicine, Edwards Comprehensive Cancer Center, Joan C. Edwards College of Medicine,
Product
ipilimumab-nivolumabAbstract
Use of immunotherapy-based combos in advanced renal cell carcinoma in a Galician center.Org: Servicio de Oncologia Medica, Hospital Universitario de Santiago, Santiago De Compostela, Spain, Medical Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain, Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain, Department of Oncologic Pharmacy, Santiago de Compostela University Hospital, Santiago De Compostela, Spain, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago De Compostela, Spain,